市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Erasca, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.8
| 分析师共识 | -3.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.75 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 11.69% |
| 机构持股比例 | 84.38% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Logos Global Management Lp | 31 Dec 2025 | 13,000,000 |
| Arch Venture Management, Llc | 31 Dec 2025 | 11,055,554 |
| Vivo Capital, Llc | 31 Dec 2025 | 9,273,428 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 20.00 (Clear Street, -6.93%) | 购买 |
| 中 | 17.50 (-18.57%) | |
| 低 | 15.00 (HC Wainwright & Co., -30.20%) | 购买 |
| 平均值 | 17.50 (-18.57%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 12.54 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Clear Street | 06 Mar 2026 | 20.00 (-6.93%) | 购买 | 15.47 |
| HC Wainwright & Co. | 26 Jan 2026 | 15.00 (-30.20%) | 购买 | 9.61 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Feb 2026 | 公告 | Erasca to Present at Upcoming Conferences in February |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合